Reuters logo
10 个月内
BRIEF-Altor Bioscience and NantKwest announces co-development agreement
2016年10月4日 / 下午3点17分 / 10 个月内

BRIEF-Altor Bioscience and NantKwest announces co-development agreement

1 分钟阅读

Oct 4 (Reuters) - NantKwest Inc:

* Financial terms of this co-development are not disclosed

* Development agreement to advance innovative natural killer cell combination immunotherapies for the treatment of cancer

* Altor and Co will exclusively collaborate on development of therapeutic applications combining altor's proprietary IL-15 superagonist

* Altor, Co to also exclusively collaborate single-chain t cell receptor/IL-2 fusion protein products with Co's proprietary NK cell therapy platforms Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below